Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
GLTO Stock Chart & Stats
$29.68
-$0.21(-3.82%)
At close: 4:00 PM EST
$29.68
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.01 - $38.33
Previous CloseN/A
Volume2.41K
Average Volume (3M)5.26M
Market Cap
$1.69B
Enterprise Value$41.22M
Total Cash (Recent Filing)$7.61M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Mar 30, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding60,240,070
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.24K
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$44.00Price Target Upside48.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Development ReadinessAcquisition of Damora and sufficient funding position the company to progress DMR-001 toward pivotal trials, supporting a credible path to potential commercialization.
Therapeutic DifferentiationLead candidate DMR-001 combines higher potency against both major CALR mutant types with a subcutaneous formulation, offering a potential clinical and commercial edge over an intravenous-only rival.
Unmet Clinical NeedTargeting mutant CALR-driven essential thrombocythemia and myelofibrosis could address a clear treatment gap given widespread use of hydroxyurea, which is not disease-modifying and can have tolerability and safety concerns.
Bears Say
Competing Therapeutic ModalitiesRival programs that include both monoclonal antibodies and bispecific T-cell engagers increase uncertainty over which approach will dominate clinical practice, heightening adoption risk for any single therapy.
Direct CompetitionA larger rival developing advanced mutCALR therapies presents direct competition that could seize market share and complicate the company's commercial prospects.
First-mover Clinical AdvantageA first-mover competitor with demonstrated clinical progress targeting the same mutation may set treatment standards and limit uptake of later entrants.
Galecto News
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $2.01 and its highest was $38.33 in the past 12 months.
What is Galecto’s market cap?
Galecto’s market cap is $1.69B.
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Mar 30, 2026 which is in 25 days.
How were Galecto’s earnings last quarter?
Galecto released its earnings results on Nov 06, 2025. The company reported -$2.36 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.36.
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate is -0.11.
How many shares outstanding does Galecto have?
Galecto has 60,240,070 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Galecto reported an EPS of -$2.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.948%.
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galecto Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (48.25% Upside)
$44.00 (48.25% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-114.81%
Trailing 12-Months
Asset Growth
-49.84%
Trailing 12-Months
Company Description
Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
GLTO Stock 12 Month Forecast
Average Price Target
$44.00
▲(48.25% Upside)
Technical Analysis
Ownership Overview
16.09% Insiders
0.30% Mutual Funds
0.23% Other Institutional Investors
83.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---